Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Ibrahim Ethem Pinar"'
Autor:
Vildan Gursoy, Sevil Sadri, Hatice Demirci Kucukelyas, Fazıl Cagri Hunutlu, Ibrahim Ethem Pinar, Zafer Serenli Yegen, Nihan Alkış, Tuba Ersal, Ridvan Ali, Vildan Ozkocaman, Fahir Ozkalemkas
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Myelodysplastic syndrome (MDS) is a heterogeneous spectrum of clonal hematopoietic disorders with varying degrees of cytopenia and morphologic dysplasia. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a prognostic marker i
Externí odkaz:
https://doaj.org/article/f256b920af054803b5fa05a44c387829
Autor:
Vildan Gursoy, Fahir Ozkalemkas, Aslı Gorek Dilektaslı, Ezgi Demirdogen, Vildan Ozkocaman, Ibrahim Ethem Pinar, Beyza Ener, Halis Akalin, Esra Kazak, Rıdvan Ali
Publikováno v:
Bulletin of the National Research Centre, Vol 47, Iss 1, Pp 1-5 (2023)
Abstract Background Tuberculosis (TB) is a systemic infectious disease that is caused by Mycobacterium tuberculosis and which can affect many tissues and organs. Despite the development of curative and preventive therapies in recent years, TB continu
Externí odkaz:
https://doaj.org/article/c9f3f37489e542eda91e93cb26c47917
Autor:
Ömer CANDAR, Vildan OZKOCAMAN, Tuba ERSAL, Tuğçe ZOR TURNA, İbrahim Ethem PINAR, Cumali YALÇIN, Bedrettin ORHAN, Sinem ÇUBUKÇU, Tuba GÜLLÜ KOCA, Rıdvan ALİ, Fahir ÖZKALEMKAŞ
Publikováno v:
Turkish Journal of Internal Medicine. 5:70-76
Background: Dapsone is a second-line therapy for immune thrombocytopenia (ITP). It is cost-effective, with a response rate comparable to other drugs used as second-line therapy, such as azathioprine, danazol, cyclophosphamide, cyclosporine, vincristi
Autor:
Tuba ERSAL, Fahir ÖZKALEMKAŞ, Vildan OZKOCAMAN, İbrahim Ethem PINAR, Cumali YALÇIN, Bedrettin ORHAN, Ömer CANDAR, Sinem ÇUBUKÇU, Tuba GÜLLÜ KOCA, Rıdvan ALİ
Publikováno v:
Turkish Journal of Internal Medicine. 5:109-116
Background Hairy cell leukemia (HCL) is an uncommon neoplasm representing approximately 2% leukemias and
Autor:
Ezel ELGUN, Vildan GÜRSOY, Tuba ERSAL, İbrahim Ethem PINAR, Fahir ÖZKALEMKAŞ, Vildan OZKOCAMAN
Publikováno v:
Uludağ Üniversitesi Tıp Fakültesi Dergisi. 48:231-237
Otolog hematopoetik kök hücre nakli (OHKHN) relaps/refrakter Hodgkin lenfoma (HL) için kurtarma tedavisi sonrasında uygulanılan standart bir tedavidir. Çalışma ile merkezimizdeki relaps/refrakter HL tanılı OHKHN uygulanılan hastaların has
Autor:
Tuba ERSAL, Vildan OZKOCAMAN, Cumali YALÇIN, Bedrettin ORHAN, Ömer CANDAR, Sinem ÇUBUKÇU, Tuba GÜLLÜ KOCA, Fazıl Cagrı HUNUTLU, Şeyma YAVUZ, İbrahim Ethem PINAR, Rıdvan ALİ, Fahir ÖZKALEMKAŞ
Publikováno v:
Uludağ Üniversitesi Tıp Fakültesi Dergisi.
İlk oral proteazom inhibitörü (PI) olan iksazomib, lenalidomid ve deksametazon (IRd) ile kombinasyon halinde relaps refrakter multipl miyelomun (RRMM) tedavisi için onaylanmıştır. Bununla birlikte, klinik çalışma sonuçları her zaman gerç
Autor:
Mehmet Baysal, Vildan Gürsoy, Fazil Cagri Hunutlu, Buket Erkan, Ufuk Demirci, Volkan Bas, Sedanur Karaman Gulsaran, Ibrahim Ethem Pinar, Tuba Ersal, Tugcan Alp Kirkizlar, Emine Ikbal Atli, Hakki Onur Kirkizlar, Elif G Ümit, Hakan Gürkan, Vildan Ozkocaman, Fahir Ozkalemkas, Ahmet Muzaffer Demir, Ridvan Ali
Publikováno v:
Annals of Hematology. 101:1049-1057
Acute promyelocytic leukemia (APL) differs from other forms of acute myeloid leukemia (AML), including coagulopathy, hemorrhage, disseminated intravascular coagulation (DIC), and treatment success with all-trans retinoic acid (ATRA). Despite ATRA, ea
Autor:
Tuba GÜLLÜ KOCA, İbrahim Ethem PINAR, Tuba ERSAL, Cumali YALÇIN, Bedrettin ORHAN, Ömer CANDAR, Sinem ÇUBUKÇU, Fazıl Cagrı HUNUTLU, Rıdvan ALİ, Vildan OZKOCAMAN, Fahir ÖZKALEMKAŞ
Publikováno v:
Uludağ Üniversitesi Tıp Fakültesi Dergisi.
Kronik Myeloid Lösemide (KML), etyolojisinde sorumlu tirozin kinaz aktivitesi gösteren bcr-abl füzyon geninin keşfinden sonra, bu aktiviteyi inhibe eden ilaçların keşfiyle, daha uzun sağkalım sürelerine ulaşılabilmiştir. Bu ilaçlarla te
Autor:
İbrahim Ethem Pinar, Vildan Ozkocaman, Tuba Ersal, Rıdvan Ali, Fahir Özkalemkaş, Bedrettin Orhan, Ömer Candar, Cumali Yalçin
Publikováno v:
Uludağ Üniversitesi Tıp Fakültesi Dergisi. 47:189-193
Relaps veya refrakter akut lösemide klofarabin bazlı kurtarma tedavilerinin genel yanıt oranları %17-48 arasında değişmektedir. Çalışmamızda relaps veya refrakter akut lösemi tanılı hastalarda klofarabin bazlı kurtarma tedavisi sonras
Autor:
Volkan Karakuş, Omur Gokmen Sevindik, Aylin Karatas, Emel Merve Yenihayat, Merve Gokcen Polat, Serhat Çelik, Ibrahim Ethem Pinar, Ali Dogan, Idris İnce, Umit Yavuz Malkan, Utku Iltar, Demircan Özdalcı Ozdalcı, Özgür Mehtap, Ramazan Erdem, Murat Kacmaz, Fatma Aykas, Berna Ozturk, Burak Deveci, Aydan Akdeniz, Hale Bulbul, Sureyya Yigit Kaya, Ferda Can, Zeynep Guven, Ceyda Aslan, Muzaffer Keklik, Fahir Ozkalemkas, Hakan Goker, İnci Alacacıoğlu
Introduction: To investigate the demographics and treatment details of the acute myeloid leukemia (AML) patients who were diagnosed and followed up in Turkey. Methods: Patients who were recorded on the database of Turkish AML Registry project were in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d669e7e8d417ece6ac4980d03e59a42
https://hdl.handle.net/20.500.12511/10631
https://hdl.handle.net/20.500.12511/10631